Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar 18;5(3):928-48.
doi: 10.3390/nu5030928.

Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches

Dragana Nikolic  1 , Niki Katsiki, Giuseppe Montalto, Esma R Isenovic, Dimitri P Mikhailidis, Manfredi Rizzo
Affiliations
Review

Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches

Dragana Nikolic et al. Nutrients. .

Abstract

Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in these subjects. Statins are the lipid-lowering drug of choice. Also, anti-obesity and lipid lowering drugs other than statins could be useful in these patients. However, the effects of anti-obesity drugs on CVD risk factors remain unclear. We review the clinical significance of sdLDL in being overweight and obesity, as well as the efficacy of anti-obesity drugs on LDL subfractions in these individuals; a short comment on HDL subclasses is also included. Our literature search was based on PubMed and Scopus listings. Further research is required to fully explore both the significance of sdLDL and the efficacy of anti-obesity drugs on LDL subfractions in being overweight, obesity and MetS. Improving the lipoprotein profile in these patients may represent an efficient approach for reducing cardiovascular risk.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosolova H., Nussbaumerova B. Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. EPMA J. 2011;2:15–26. doi: 10.1007/s13167-011-0066-1. - DOI - PMC - PubMed
    1. Charakida M., Finer N. Drug treatment of obesity in cardiovascular disease. Am. J. Cardiovasc. Drugs. 2012;12:93–104. doi: 10.2165/11599000-000000000-00000. - DOI - PubMed
    1. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., Witztum J.L. Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol. 2008;51:1512–1524. doi: 10.1016/j.jacc.2008.02.034. - DOI - PubMed
    1. Despres J.P. Cardiovascular disease under the influence of excess visceral fat. Crit. Pathw. Cardiol. 2007;6:51–59. doi: 10.1097/HPC.0b013e318057d4c9. - DOI - PubMed
    1. Magkos F., Mohammed B.S., Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int. J. Obes. (Lond.) 2008;32:1655–1664. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources